Clinical Trial Update: Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating inhaled mometasone for reducing vaso-occlusive events in sickle cell disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• mometasone (mometasone)

Snippet

Sponsor: Jeffrey Glassberg | Conditions: Sickle Cell Disease | Phase 2 | Status: COMPLETED